Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings

ObjectiveStereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy (SBRT), is now a standard treatment option for patients with stage I non-small cell lung cancer or oligometastatic lung tumor who are medically inoperable or medically operable but refuse surgery. When mass-like consolidation is observed on follow-up CT after SABR, it is sometimes difficult to differentiate tumor recurrence from SABR-induced pulmonary fibrosis. In this study, we evaluated the role of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) in differentiating tumor recurrence from radiation fibrosis after SABR.MethodsBetween June 2006 and June 2009, 130 patients received SABR for stage I non-small cell lung cancer or metastatic lung cancer at our institution. Fifty-nine patients of them were imaged with FDG-PET/CT after SABR. There were a total of 137 FDG-PET/CT scans for retrospective analysis. The FDG uptake in the pulmonary region was assessed qualitatively using a 3-point scale (0, none or faint; 1, mild; or 2, moderate to intense), and the shape (mass-like or non mass-like) was evaluated. For semi-quantitative analysis, the maximum standardized uptake value (SUVmax) was calculated.ResultsSixteen of 59 patients had local failure. In recurrent tumor, the combination of intensity grade 2 and mass-like shape was most common (21/23; 91 %). By contrast, in cases of radiation fibrosis, the combination of intensity grade 0 or 1 and non mass-like shape was most common (48/59; 81 %). The SUVmax of tumor recurrence after 12 months was significantly higher than that of radiation fibrosis (8.0 ± 3.2 vs. 2.1 ± 0.9, p < 0.001), and all tumor recurrence showed the SUVmax > 4.5 at diagnosis of local failure. At ≥12 months after SABR, these two variables, the combination of intensity 2 and mass-like FDG uptake or SUVmax > 4.5 acquired a significant high predictive value of local recurrence, finding sensitivity 100 % and specificity 100 % for both of them.ConclusionsThe combination of FDG uptake patterns and SUVmax was useful for distinguishing tumor recurrence from radiation fibrosis after SABR.

[1]  Hiroki Shirato,et al.  Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? , 2011, International journal of radiation oncology, biology, physics.

[2]  Johannes A. Langendijk,et al.  Clinical Investigation : Thoracic Cancer Residual 18 F-FDG-PET Uptake 12 Weeks After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control , 2012 .

[3]  A. Yoshizawa,et al.  Salvage Lung Resection for Non-small Cell Lung Cancer After Stereotactic Body Radiotherapy in Initially Operable Patients , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  M. Hiraoka,et al.  Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors , 2007, International Journal of Clinical Oncology.

[5]  J. Bradley,et al.  Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. , 2011, European journal of radiology.

[6]  P. Lambin,et al.  Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. , 2009, European journal of cancer.

[7]  G. Gladish,et al.  Radiation injury of the lung after three-dimensional conformal radiation therapy. , 2002, AJR. American journal of roentgenology.

[8]  H. Shirato,et al.  Stereotactic Body Radiotherapy (SBRT, BED ≥ 100 Gy) for Operable Stage I Non-Small Cell Lung Cancer: Is SBRT Comparable to Surgery? , 2007 .

[9]  J. Petersen,et al.  Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer , 2005 .

[10]  John Cho,et al.  Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. , 2012, International journal of radiation oncology, biology, physics.

[11]  S. Ou,et al.  Natural history of stage I non-small cell lung cancer: implications for early detection. , 2007, Chest.

[12]  R. Timmerman,et al.  FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer , 2007 .

[13]  J. Bishop,et al.  Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. , 1995, International journal of radiation oncology, biology, physics.

[14]  Aaron Ward,et al.  Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  David J. Yang,et al.  Detecting recurrent or residual lung cancer with FDG-PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  L. Gaspar,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Kunieda,et al.  Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[18]  K. Togashi,et al.  Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  M. Kokubo,et al.  Surgical Treatment of Local Recurrence After Stereotactic Body Radiotherapy for Primary and Metastatic Lung Cancers , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  M. Hiraoka,et al.  Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. , 2004, Radiology.

[21]  B. Yaremko,et al.  Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis. , 2011, International journal of radiation oncology, biology, physics.

[22]  R. Timmerman,et al.  FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. , 2005, Lung cancer.

[23]  B Ghaye,et al.  Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. , 1999, The European respiratory journal.